{"entity":{"id":"nct05864014","kind":"trial","name":"Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.","aka":[],"tldr":"A phase 3 trial of Hetrombopag in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.","summary":"Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors. is a phase 3 interventional study registered as NCT05864014 by Jiangsu HengRui Medicine Co., Ltd., with 213 participants enrolled, started 2023-04-25 and due to reach its primary completion in 2025-03-03. Interventions recorded: Hetrombopag, Hetrombopag plus Placebo and Placebo.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05864014","url":"https://clinicaltrials.gov/study/NCT05864014"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05864014","phase":"3","setting":"Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Adults With Solid Tumors.","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","enrolled":213,"outcomes":[]},"route":"/trials/nct05864014/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}